Osteopontin, a multi-faceted molecule;L'ostéopontine, une molécule aux multiples facettes

Medecine/Sciences

Volumn 21, Issue 10, 2005, Pages 832-838

  Chabas, Dorothée ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CASEIN KINASE II; GLYCOPROTEIN; HERMES ANTIGEN; OSTEOPONTIN; PHOSPHOPROTEIN; SECRETED PHOSPHOPROTEIN 1; SMALL INTEGRIN BINDING LIGAND N LINKED GLYCOPROTEIN; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; AUTOIMMUNE DISEASE; BREAST CANCER; CELL ADHESION; CELL MIGRATION; CORTICAL BONE; COW; CYTOKINE PRODUCTION; DISEASE ACTIVITY; ENCEPHALOMYELITIS; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HERPES; INFLAMMATION; LISTERIA; MOUSE; NONHUMAN; PHENOTYPE; PLEIOTROPY; PROSTATE CANCER; PROTEIN CROSS LINKING; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; SIALYLATION; TUBERCULOSIS;

ANIMALIA; BOVINAE; HERPES; LISTERIA;

EID: 27144469943     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20052110832     Document Type: Review

References (72)

1. Herring K. Some studies on mucosubstances of bovine cortical bone. Biochem J 1963; 89: 405-14.
2. Herring GM. A comparison of bone matrix and tendon with particular reference to glycoprotein content. Biochem J 1976; 159: 749-55.
3. Sorensen ES, Petersen TE. Posttranslational modifications of bovine osteopontin: identification of 28 phosphorylation and 3 O-glycosylation sites. Protein Sci 1995; 4: 2040-9.
4. Sorensen ES, Petersen TE. Phosphorylation, glycosylation and transglutaminase sites in bovine osteopontin. Ann NY Acad Sci 1995; 21: 363-6.
5. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993; 7: 1475-82.
6. Fisher LW, Torchia DA, Fohr B, et al. Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. Biochem Biophys Res Commun 2001; 280: 460-5.
7. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996; 271: 509-12.
8. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860-4.
9. Zohar R, Suzuki N, Suzuki K, et al. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 2000; 184: 118-30.
10. Hwang SM, Lopez CA, Heck DE, et al. Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem 1994; 269: 711-5.
11. Bendeck MP, Irvin C, Reidj M, et al. Smooth cell matrix metalloproteinase production is stimulated via alpha(v)-beta(3) integrin. Arterioscler Thromb Vasc Biol 2000; 20: 1467-72.
12. Swanson GJ, Nomura S, Hogan BL. Distribution of expression of 2AR (osteopontin) in the embryonic mouse inner ear revealed by in situ hybridisation. Hear Res 1989; 41: 169-77.
13. Shin SL, Cha JH, Chun MH, et al. Expression of osteopontin mRNA in the adult rat brain. Neurosci Lett 1999; 273: 73-6.
14. Lee MY, Choi JS, Lim SW, et al. Expression of osteopontin mRNA in developing rat brainstem and cerebellum. Cell Tissue Res 2001; 306: 179-85.
15. Ichikawa H, Yamashita K, Takano-Yamamoto T, Sugimoto T. Osteopontin-immunoreactivity in the rat trigeminal ganglion and trigeminal sensory nuclei. Brain Res 2001; 919: 147-54.
16. Lopez CA, Olson ES, Adams JC, et al. Osteopontin expression detected in adult cochleae and inner ear fluids. Hear Res 1995; 85: 210-22.
17. Ding Q, Stewart J Jr, Prince CW, et al. Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain : differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res 2002; 62: 5336-43.
18. Zohar R, Lee W, Arora P, et al. Single cell analysis of intracellular osteopontin in osteogenic cultures of fetal rat calvarial cells. J Cell Physiol 1997; 170: 88-100.
19. O'Regan AW, Hayden JM, Berman JS. Osteopontin augments CD3-mediated interferon-gamma and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leuk Biol 2000; 68: 495-502.
20. Hunter GK, Kyle CL, Goldberg HA. Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J 1994; 300: 723-8.
21. Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 2000; 275: 20197-203.
22. Hunter GK, Pampena DA, Goldberg HA. Osteopontin meeting, 2002.
23. Beshensky AM, Wesson JA, Worcester EM, et al. Effects of urinary macromolecules on hydroxyapatite crystal formation. J Am Soc Nephrol 2001; 12: 2108-16.
24. Wesson JA, Johnson RJ, Mazzali M, et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 2003; 14: 139-47.
25. Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 2001; 1552: 61-85.
26. Furger KA, Menon RK, Tuckl AB, et al. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001; 1: 621-32.
27. Rudland PS, Platt-Higgins A, El-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002; 62: 3417-27.
28. Euer N, Schwirzke M, Evtimova V, et al. Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines. Anticancer Res 2002; 22: 733-40.
29. Hotte SJ, Winquist EW, Stitt L, et al. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002; 95: 506-12.
30. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002; 94: 513-21.
31. Rittling SR BB, Chen Y. Role of host osteopontin in tumorigenesis. Osteopontin meeting, 2002.
32. Speer MY, McKee MD, Guldberg RE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 2002; 196: 1047-55.
33. Steitz SA, Speer MY, McKee MD, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 2002; 161: 2035-46.
34. Murry CE, Giachelli CM, Schwartz SM, Vracko R. Macrophages express osteopontin during repair of myocardial necrosis. Am J Pathol 1994; 145: 1450-62.
35. Trueblood NA, Xie Z, Communal C, et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res 2001; 88: 1080-7.
36. Markert JM, Fuller CM, Gillespie GY, et al. Differential gene expression profiling in human brain tumors. Physiol Genomics 2001; 5: 21-33.
37. Saitoh Y, Kuratsu J, Takeshima H, et al. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 1995; 72: 55-63.
38. Wang X, Louden C, Yue TL, et al. Delayed expression of osteopontin after focal stroke in the rat. J Neurosci 1998; 18: 2075-83.
39. Ellison JA, Velier JJ, Spera P, et al. Osteopontin and its integrin receptor alpha(v)beta3 are upregulated during formation of the glial scar after focal stroke. Stroke 1998; 29: 1698-707.
40. Ellison JA, Barone FC, Feuerstein GZ. Matrix remodeling after stroke. De novo expression of matrix proteins and integrin receptors. Ann NY Acad Sci 1999; 890: 204-22.
41. Karpuj MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002; 8: 143-9.
42. Kim SY, Choi YS, Choi JS, et al. Osteopontin in kainic acid-induced microglial reactions in the rat brain. Mol Cells 2002; 13: 429-35.
43. Boskey AL, Spevak L, Paschalis E, et al. Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int 2002; 71: 145-54.
44. Yoshitake H, Rittling SR, Denhardt DT, Noda M. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci USA 1999; 96: 8156-60.
45. Ihara H, Denhardt DT, Furuya K, et al. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J Biol Chem 2001; 276: 13065-71.
46. Nemoto H, Rittling SR, Yoshitake H, et al. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 2001; 16: 652-9.
47. Wu Y, Denhardt DT, Rittling SR. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 2000; 83: 156-63.
48. Morimoto I, Sasaki Y, Ishida S, et al. Identification of the osteopontin gene as a direct target of TP53. Genes Chromosomes Cancer 2002; 33: 270-8.
49. Ahn JH, Lee Y, Jeon C, et al. Identification of the genes differentially expressed in human dendritic cell subsets by cDNA subtraction and microarray analysis. Blood 2002; 100: 1742-54.
50. Patarca R, Freeman GJ, Singh RP, et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med 1989; 170: 145-61.
51. Nagai S, Hashimoto S, Yamashita T, et al. Comprehensive gene expression profile of human activated T(h)1- and T(h)2-polarized cells. Int Immunol 2001; 13: 367-76.
52. O'Regan AW, Nau GJ, Chupp GL, Berman JS. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today 2000; 21: 475-8.
53. O'Regan AW, Chupp GL, Lowry JA, et al. Osteopontin is associated with T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J Immunol 1999; 162: 1024-31.
54. Masutani K, Akahoshi M, Tsuruya K, et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001; 44: 2097-106.
55. Okada H, Moriwaki K, Konishi K, et al. Tubular Osteopontin expression in human glomerulonephritis and renal vasculitis. Am J Kidney Dis 2000; 36: 498-506.
56. Lampe MA, Patarca R, Iregui MV, Cantor H. Polyclonal B cell activation by the Eta-1 cytokine and the development of systemic autoimmune disease. J Immunol 1991; 147: 2902-6.
57. Wuthrich RP, Fan X, Ritthaler T, et al. Enhanced Osteopontin expression and macrophage infiltration in MRL-Fas(lpr) mice with lupus nephritis. Autoimmunity 1998; 28: 139-50.
58. Iizuka J, Katagiri Y, Tada N, et al. Introduction of an osteopontin gene confers the increase in B1 cell population and the production of anti-DNA autoantibodies. Lab Invest 1998; 78: 1523-33.
59. Weber GF, Cantor H. Differential roles of osteopontin/Eta-1 in early and late lpr disease. Clin Exp Immunol 2001; 126: 578-83.
60. Giachelli CM, Lombardi D, Johnson RJ, et al. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 1998; 152: 353-8.
61. Weiss JM, Renkl AC, Maier CS, et al. Osteopontin is involved in the initiation of cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell migration to lymph nodes. J Exp Med 2001; 194: 1219-29.
62. Yumoto K, Ishijima M, Rittling SR, et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci USA. 2002; 99: 4556-61.
63. O'Regan AW, Hayden JM, Body S, et al. Abnormal pulmonary granuloma formation in osteopontin-deficient mice. Am J Respir Crit Care Med 2001; 164: 2243-7.
64. Potter MR, Rittling SR, Denhardt DT, et al. Role of osteopontin in murine Lyme arthritis and host defense against Borrelia burgdorferi. Infect Immun 2002; 70: 1372-81.
65. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294: 1731-5.
66. Vogt MH, Lopatinskaya L, Smits M, et al. Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol 2003; 53: 819-22.
67. Vogt MH, Floris S, Killestein J, et al. Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 2004; 155: 155-60.
68. Comabella M, Pericot I, Goertsches R, et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 2005; 158: 231-9.
69. Selvaraju R, Bernasconi L, Losberger C, et al. Osteopontin is upregulated during in vivo demyelination and remyelination and enhances myelin formation in vitro. Mol Cell Neurosci 2004; 25: 707-21.
70. Steinman L, Youssef S, Van Venrooij N, et al. Response to comment on the influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2003; 299: 1845b.
71. Chabas D. L'ostépontine dans la sclérose en plaques. Thèse d'immunologie. Paris: UPMC, 2003: 116 p.
72. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 1986; 83: 8819-23.